Related Experiment Video

Updated: Jun 8, 2026

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
07:03

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease

Published on: July 19, 2024

Nonalcoholic fatty liver disease: a challenge for pediatricians

K Widhalm1, E Ghods

  • 1Division of Pediatric Nutrition and Prevention, Department of Pediatrics, Medical University of Vienna, Vienna, Austria. kurt.widhalm@meduniwien.ac.at

International Journal of Obesity (2005)
|September 15, 2010
PubMed

Insights

Childhood obesity drives nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Early, noninvasive diagnosis in high-risk children and obesity prevention are key strategies for managing pediatric NAFLD.

Area of Science:

  • Pediatric Gastroenterology
  • Hepatology
  • Public Health

Background:

  • Nonalcoholic fatty liver disease (NAFLD) is the leading cause of pediatric liver disease, linked to rising childhood obesity rates.
  • Nonalcoholic steatohepatitis (NASH) is increasingly recognized globally, posing a growing risk for end-stage liver disease in children.
  • Despite epidemiological trends, significant advancements in pediatric NAFLD/NASH diagnosis and treatment remain limited.

Purpose of the Study:

  • To review current diagnostic and management strategies for pediatric NAFLD and NASH.
  • To highlight the role of noninvasive biomarkers and diagnostic criteria for early identification.
  • To discuss emerging pharmacological, surgical, and novel therapeutic approaches.

Main Methods:

  • Comprehensive literature search using PubMed.
  • Inclusion of review articles and relevant research studies.
  • Focus on diagnostic and management aspects of pediatric NAFLD/NASH.

Main Results:

  • Pediatric NAFLD prevalence ranges from 3% overall to 50% in obese children.
  • Noninvasive biomarkers and biochemical/immunological criteria can identify NAFLD/NASH patients, potentially reducing invasive testing by half.
  • Pharmacological and surgical interventions are increasingly utilized, while novel treatments like probiotics require further investigation.

Conclusions:

  • Early diagnosis via noninvasive screening in high-risk pediatric populations is crucial for effective NAFLD management.
  • Understanding early growth and hepatic metabolism is vital for addressing pediatric NAFLD.
  • Childhood obesity prevention is the most effective long-term strategy for treating and preventing pediatric NAFLD.
Abstract

More Related Videos

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis06:26

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Chronic Pancreatitis I: Introduction01:25

Chronic Pancreatitis I: Introduction

Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...